StockNews.com downgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday morning. Separately, Scotiabank assumed ...

Theravance Biopharma continued to make progress with the open-label enrollment of its ampreloxetine Phase 3 clinical study for the treatment of symptomatic nOH in patients with Multiple System Atrophy ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

Laboratory of Neuropsychiatry, Mental Health Centre Copenhagen, Mental Health Services in the Capital Region of Denmark and University of Copenhagen, Frederiksberg 2000, Denmark Copenhagen Center for ...

Suppressing striatal cholinergic interneurons or administering the muscarinic antagonist Procyclidine significantly reduces tremors caused by nicotine withdrawal. According to the World Health ...

The pair will study if blocking a receptor in the brain (M5 muscarinic) will prevent or address opioid addiction. The effect could be the development of a medicine that allows safer use ...

Background: Hallucinogen persisting perception disorder (HPPD) is characterized by the re-emergence of perceptual symptoms experienced during acute hallucinogen intoxication following drug cessation.

Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and Disruptors (26-50) Specialized Leaders (51-75) Emerging Powerhouses (76-100) ...